High flow therapy versus hypertonic saline in bronchiolitis: randomised controlled trial

Mercedes Bueno Campaña, Jorge Olivares Ortiz, Cristina Notario Muñoz, Marta Rupérez Lucas, Adelaida Fernández Rincón, Olga Patiño Hernández, Cristina Calvo Rey

ABSTRACT
Objective To demonstrate that heated humidified high-flow nasal cannula (HHHFNC) is superior to inhaled hypertonic saline solution (HSS) in improving respiratory distress in moderate bronchiolitis. In addition, it could improve comfort and reduce length of hospital stay (LOS) and admission to Paediatric Intensive Care Unit (PICU).

Design Randomised Clinical Trial from 1 October 2010 to 31 December 2012.

Setting Two urban secondary (no PICU available) paediatric hospitalisation units.

Patients Hospitalised children aged up to 6 months with moderate acute bronchiolitis (Respiratory Distress Assessment Instrument, RDAI ≥4).

Intervention Patients were randomised to HHHFNC or HSS. All of them received epinephrine as bronchodilator.

Main outcomes Primary outcome was difference in mean Respiratory Assessment Change Score (RACS) between both groups measured in six previously defined consecutive moments. Secondary outcomes were difference in mean comfort scores in this period, LOS and rate of PICU admission.

Results Seventy-five previously healthy patients were enrolled. Mean age was 2.4 months (95% CI 2.04 to 2.76). 43 were allocated to HSS group and 32 in HHHFNC. Data of 1 patient were lost, and 8 changed group over the study period. Intention-to-treat principle was applied. There were no significant differences in mean RACS and mean comfort scores between groups at the evaluation points. Median LOS or PICU admission rate were similar in both groups. No adverse events were observed.

Conclusions HHHFNC was not superior to HSS in the treatment of moderate acute bronchiolitis with respect to severity and comfort scores, LOS or PICU admission rate.

Clinical Trial Registration ClinicalTrials.gov Identifier NCT01873144.

INTRODUCTION
Bronchiolitis is the most common lower respiratory tract infection in infants and represents an important cause of hospitalisation in this age group. It is estimated that 11–12% of all infants are affected in the first year of life, with 1–2% requiring hospitalisation. Of those admitted, 10% of previously healthy infants and 36% of those with comorbidities will require Paediatric Intensive Care Unit (PICU), with 1% of them dying. Pathological findings include airway wall swelling, increased mucus production which eventually leads to airway obstruction, atelectasis and impaired gas exchange. Standard treatment remains supportive and includes ensuring adequate oxygen exchange, fluid intake and feeding. Only in moderate severe bronchiolitis, trial with inhaled epinephrine is accepted.

Considering the pathological events, any therapeutic modality, like hypertonic saline solution (HSS), which improves the clearance of airway secretions may be beneficial. In a recent meta-analysis, it was concluded that HSS should be considered an effective and safe treatment in mild-to-moderate acute viral bronchiolitis.

There is another promising therapeutic option, heated humidified high-flow nasal cannula (HHHFNC) oxygen therapy. It provides warmed and humidified gas with high flow, in theory improving work of breathing and comfort status. There have been several randomised trials which have demonstrated its utility in bronchiolitis.

We designed a clinical trial to demonstrate HHHFNC superiority versus HSS in improving respiratory distress in infants aged less or equal to 6 months hospitalised with moderate bronchiolitis.

What is already known on this topic
- In bronchiolitis no therapy has conclusively shown to alter the course of the disease or its major outcomes.
- Standard treatment remains supportive.
- Considering pathological findings, any therapeutic modality which improves the clearance of airway secretions may be beneficial.

What this study adds
Heated humidified high-flow nasal cannula oxygen therapy is not superior to inhaled hypertonic saline solution in the treatment of infants diagnosed of moderate bronchiolitis.
PATIENTS AND METHODS

We conducted a controlled randomised clinical trial from 1 October 2010 to 31 December 2012 in two secondary paediatric hospitalisation units of Madrid (Spain). The participant hospitals attend a total population of 51 269 children less than 14 years of age with no PICU available. The study was funded by Department of Health, Social Policy and Equality of Spain, Grant EC11-437 and approved by the Medical Ethics Committee of both centres.

Children aged 6 months or less presenting with moderate bronchiolitis (as defined by McConnachie20) and who met admission criteria were eligible for inclusion in the study. Moderate respiratory distress was defined by a Respiratory Distress Assessment Instrument (RDAI) score of four or greater (see online supplementary eTable 1).21 Exclusion criteria were: history of prematurity (gestational age less or equal 37 weeks), chronic lung disease, cystic fibrosis, congenital heart disease, neuromuscular disease, airway anomalies, immunodeficiency, and those requiring immediate intubation and ventilation. Informed consent was obtained from parents before enrolment. The study was terminated at discharge or if, at any time, the clinical condition made the transfer to PICU necessary. Criteria for admission, discharge and transfer to PICU are shown in online supplementary eTable 2. Epidemiological and clinical data were recorded. Rapid test for respiratory syncytial virus and influenza in nasal swab was performed in all the patients.

Our nurses were trained in the clinical scoring system to ensure consistency and accuracy of scoring. There were three shifts of nurses every day.

Study design

Once included in the trial, participants received a nebulisation of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of normal saline (NS) (0.9%) if they had not received it previously. Then a computer-generated list was used22 by investigators for simple allocation of the participants to two groups (ratio 1:1): (1) HSS Group: Nebulised epinephrine 1/1000 plus 2 mL of HS(3%) every 4 h. (2) HHHFNC Group: HHHFNC with flow depending on weight (Tidal volume x respiratory rate (RR)×0.9) and nebulised epinephrine 1/1000 plus 2 mL of NS (0.9%) every 4 h. Other treatments provided were intravenous fluids and supplement of oxygen adjusted to achieve oxygen saturation (SatO2) of 92–96%. No other bronchodilators, antibiotic or steroid were used. In HSS Group, oxygen supplement was administrated by conventional nasal prongs, with flow not higher than 3 lpm. In HHHFNC Group flow was between 6 and 8 lpm. Physicians in charge were free to prescribe additional nebulisation or to change the patient’s study group if deemed clinically necessary. RDAI score and RR were recorded by the nurse in charge, 30 min before and 60–90 min after concluding nebulisation, over three cycles, and afterwards every 8 h for 24 h. Comfort score was recorded at admission and at the end of a nurse duty for 48 h after admission (see online supplementary eFigure 1).

Study measurements and outcomes

Respiratory Assessment Change Score (RACS) was considered as a measure of the efficacy of the assigned treatment. A RACS value of at least four has been previously defined as clinically relevant. The RACS is calculated as the difference between the RDAI score before and after treatment, plus a value of +1 for each 10% improvement (decrease) in the post-treatment RR or a value of −1 for each 10% worsening (increase) in RR.21 23 For comfort evaluation, a new scale designed by authors was used. It is based on four items: rest, feeding, alertness and facial expression (see online supplementary eTable 3). Its concordance was previously assessed in our Unit with 23 patients, obtaining a weighted κ of 0.67 between parents and nurse (no published data).

Precision Flow (Vapotherm Inc. Stevensville, Maryland, US) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the disposables used to administer HHHFNC depending on the availability. According to age, two different Fisher and Paykel nasal cannula were used in both devices, with different internane distance, and a maximum admitted flow of 6 and 8 lpm, respectively. Air leak around cannula in nares was allowed.

The variable for the primary outcome was the difference in mean RACS between groups at the evaluation points (RACS0–RACS5). For the first secondary outcome, it was the difference in mean comfort score over the monitoring period (Comfort1–Comfort6). Other secondary outcome variables were LOS in days and admission to PICU (rate) in both groups.

Statistical analysis

For sample size estimate we considered a SD of three in our primary outcome.21 Seventy-five infants were required to detect a difference in mean RACS of two points, which was considered as clinically relevant by the authors (α error of 0.05, β error of 0.2 and losses of 5%). SPSS (V19.0 for Windows) was used for statistical analysis. The intention-to-treat (ITT) principle was applied in all of our analyses. Per protocol analysis was subsequently performed. Means (SD) and median (IQR) are presented for continuous variables and rates for dichotomous ones. ANOVA with mixed model was used to study longitudinal data of RACS and comfort. This model was used to account for repeated measures within the same individual; as well this model allows working with unbalanced data, so we could include in the ITT analysis the subject with partial follow-up.24 The models included time as repeated factor, treatment as fixed effect and the interaction effect time* treatment. Post hoc pairwise comparisons of the least squared means for treatment at each point of time were contrasted with Bonferroni adjustment. PICU was compared between groups by χ2 test and LOS days were contrasted by Mann–Whitney U test; 95% CIs are shown for the main results. The method of handling missing data was complete case analysis.

RESULTS

Seventy-five infants meeting inclusion criteria were enrolled (figure 1). Their mean age was 2.4 months (95% CI 2.04 to 2.76). One patient from HSS Group was excluded from the analysis because all his data were lost. Of the 74 infants left, 42 (56.8%) were enrolled in HSS Group and 32 (43.2%) in HHHFNC Group. Both groups were similar at baseline (table 1). Sixty-six (89.2%) infants stayed in the assigned group throughout the study. Eight patients were changed to HHHFNC Group; 79.7% of patients had completed record, and only 5% of total data recorded was missing.

In mixed model for RACS, the interaction effect time-group was not statistically significant, p=0.504. Mean RACS (measure of efficacy) and mean comfort scale score were similar in both groups at the moments considered (table 2). Per protocol analysis showed significant differences in the RACS3 results (1.88; 95%CI 0.46 to 3.30) and in Comfort4 results (1.21; 95%CI 0.03 to 2.38) favourable to HSS Group.

Both groups showed a parallel trend to improvement in their RDAI scores (measure of respiratory distress) during the
**DISCUSSION**

Though our hypothesis was that HHHFNC could be superior to HSS, our results showed that in moderately ill patients, treatment with HHHFNC is no more effective than HSS as determined by a clinical scoring system (RDAI/RACS). Neither have we observed any differential benefit in comfort, LOS or rate of PICU transfer. This is the first published study that compared HHHFNC with HSS in the treatment of moderate bronchiolitis.

No therapy has conclusively shown to alter the course of bronchiolitis or its major outcomes. Epinephrine could improve comfort by reducing respiratory distress and a trial with this drug in infants suffering moderate-severe bronchiolitis is accepted in some guidelines. Among all the published literature using HSS in the treatment of bronchiolitis, 11 trials were included in a recent meta-analysis which concluded that HSS reduces 1.15 day the mean LOS, compared to NS (0.9%) and decrease significantly clinical severity score. It also conclude that despite the lack of strong evidence to recommend the routine use of HSS, its high safety profile, low cost and non-invasive administration make it a reasonable option for treating outpatient and inpatient children with bronchiolitis combined with a bronchodilator.

Based on the results obtained when used in neonatal settings, HHHFNC has been gaining considerable clinical support in the management of bronchiolitis. Retrospectives studies have demonstrated a decrease in need for intubation parallel to the increase in use of HHHFNC in acute bronchiolitis. In prospective ones, a significant improvement in respiratory scale scores, oxygen saturation and comfort were also found using HHHFNC in patients with respiratory distress admitted to the PICU. In the last few years, HHHFNC has also become popular in hospitalisation wards as a method of delivering oxygen. It is easy to use and there may also be a perception that it offers a well-tolerated, non-invasive form of respiratory support. It is, however, a relatively expensive medical device with an on-going cost for consumables.

Though reduction in admission to PICU is the most important outcome in the treatment of bronchiolitis, to show this issue would have needed a larger sample. Given the incidence of the disease and considering the economical expense of bronchiolitis every season, other major indicators such as respiratory distress, comfort and LOS might be relevant when evaluating the most cost effective therapy. So far, there have not been well designed clinical trials published, whose main objective was to determine the effect of HHHFNC in these outcomes.

Our study has strengths we would like to point out. The first one is inclusion criteria. There is general consensus on the use

---

**Table 1** Baseline characteristics of the two groups

<table>
<thead>
<tr>
<th></th>
<th>HSS (n=42)</th>
<th>HHHFNC (n=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (%)</td>
<td>22 (53)</td>
<td>11 (35)</td>
</tr>
<tr>
<td>Mean age (months)</td>
<td>2.65 (1.70)</td>
<td>1.95 (1.27)</td>
</tr>
<tr>
<td>Mean baseline RDAI score (SD)</td>
<td>6.67 (1.98)</td>
<td>7 (1.81)</td>
</tr>
<tr>
<td>Mean RR (SD)</td>
<td>51.1 (11.9)</td>
<td>49.9 (12.8)</td>
</tr>
<tr>
<td>RSV positive (%)</td>
<td>31 (74)</td>
<td>23 (72)</td>
</tr>
<tr>
<td>Mean previous illness duration (days) (SD)</td>
<td>3.13 (1.89)</td>
<td>2.90 (1.51)</td>
</tr>
</tbody>
</table>

HHHFNC, heated humidified high-flow nasal cannula; HSS, hypertonic saline solution; RSV, respiratory syncytial virus.

---

**Table 2** Primary and secondary outcomes results

<table>
<thead>
<tr>
<th></th>
<th>Mean (SE)</th>
<th>HSS (n=42)</th>
<th>HHHFNC (n=32)</th>
<th>Mean difference * (95% CI)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RACS0</td>
<td>1.24 (0.5)</td>
<td>0.91 (0.56)</td>
<td></td>
<td>0.33 (–1.17 to 1.84)</td>
<td>0.6</td>
</tr>
<tr>
<td>RACS1</td>
<td>0.95 (0.48)</td>
<td>0.38 (0.55)</td>
<td></td>
<td>0.57 (–0.89 to 2.03)</td>
<td>0.4</td>
</tr>
<tr>
<td>RACS2</td>
<td>0.36 (0.39)</td>
<td>0.39 (0.46)</td>
<td></td>
<td>0.07 (–1.12 to 1.26)</td>
<td>0.9</td>
</tr>
<tr>
<td>RACS3</td>
<td>0.19 (0.49)</td>
<td>–0.61 (0.60)</td>
<td></td>
<td>0.79 (–0.75 to 2.33)</td>
<td>0.3</td>
</tr>
<tr>
<td>RACS4</td>
<td>–0.18 (0.54)</td>
<td>1.04 (0.70)</td>
<td></td>
<td>–1.22 (–2.99 to 0.55)</td>
<td>0.2</td>
</tr>
<tr>
<td>RACS5</td>
<td>0.22 (0.48)</td>
<td>0.8 (0.64)</td>
<td></td>
<td>–0.58 (–2.187 to 1.02)</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>First secondary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comfort1</td>
<td>10.91 (0.34)</td>
<td>10.81 (0.38)</td>
<td></td>
<td>0.09 (–0.93 to 1.11)</td>
<td>0.9</td>
</tr>
<tr>
<td>Comfort2</td>
<td>11.60 (0.29)</td>
<td>11.35 (0.34)</td>
<td></td>
<td>0.25 (–0.65 to 1.12)</td>
<td>0.6</td>
</tr>
<tr>
<td>Comfort3</td>
<td>12.12 (0.34)</td>
<td>11.62 (0.41)</td>
<td></td>
<td>0.52 (–0.54 to 1.57)</td>
<td>0.3</td>
</tr>
<tr>
<td>Comfort4</td>
<td>12.45 (0.38)</td>
<td>11.87 (0.46)</td>
<td></td>
<td>0.58 (–0.61 to 1.77)</td>
<td>0.3</td>
</tr>
<tr>
<td>Comfort5</td>
<td>12.21 (0.41)</td>
<td>12.04 (0.49)</td>
<td></td>
<td>0.17 (–1.19 to 1.44)</td>
<td>0.8</td>
</tr>
<tr>
<td>Comfort6</td>
<td>12.77 (0.38)</td>
<td>12.95 (0.46)</td>
<td></td>
<td>–0.18 (–1.38 to 1.02)</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Other secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOS days median(IQR)</td>
<td>4.5 (3)</td>
<td>5 (4)</td>
<td></td>
<td>–</td>
<td>0.8</td>
</tr>
<tr>
<td>PICU n (%)</td>
<td>5 (11.9%)</td>
<td>5 (15.6%)</td>
<td></td>
<td>–</td>
<td>0.5</td>
</tr>
</tbody>
</table>

*Mean difference estimated by mixed models. p Value result of post hoc pairwise comparisons for treatment.
of the definition of McConnochie\textsuperscript{20} for bronchiolitis, based on age and clinical manifestations. Most of the studies comparing different therapies did not exclude previous wheezing\textsuperscript{16, 34} or include patients older than 6 months\textsuperscript{16, 23 34–36} in whom the diagnosis of bronchiolitis may overlap with that of any other wheezing episode. We included only first episode of bronchiolitis in 6 months or younger in order to enrol patients with a more accurate diagnosis. Consequently, we think our results could reflect more suitably the response of bronchiolitis to the tested therapy. Second, the absence of a completely objective severity clinical scale makes it difficult to assess effectiveness. The RDAI/RACS score used in our study has demonstrated a high degree of inter-rater reliability\textsuperscript{21} and was applied by the nurses in charge (which can hampered the possible bias of subjectivity) resembling the everyday practice. Finally, we decided to design a comfort scale that took into account the assessment of parents and nurses (people closest to the patient) because comfort scales frequently used are based on response to sedation, tolerance in mechanical ventilation and level of pain, which are relevant outcomes of patients in intensive care, but not outside this setting. Among limitations, the first one is that, though rate of transfer to PICU was similar in both groups and coincident with published data\textsuperscript{7} the sample size was not calculated for such an infrequent event, so we cannot draw any strong conclusion from this result. Second, eight patients were changed from the original group assigned; all of them to HHHFNC Group. This fact broke randomisation. The decision of the physician in charge had priority, and probably, the change was justified due to worsening of their clinical status and the subjective impression in staff of a better outcome in patients treated with this therapy. We applied the ITT principle but per protocol analysis subsequently performed showed results only slightly favourable to HSS at one of evaluation points. These results reinforce those obtained by the ITT analysis. Third, there could be a potential seriousness bias since we excluded patients transferred directly to PICU. Albeit we only included in our study 50\% of patients who were eligible, the rate of transfer to PICU of not included patients was quite similar to the study group. This could indicate that only logistical reasons, and not personal decisions based on severity criteria, are responsible for this event. And finally due to the techniques involved, the trial could not be blinded. The variable named RACS measures the improvement in respiratory distress. In both treatment groups, mean RACS was less than 1.5 points, far from the value of at least four defined as a clinically relevant improvement due to a therapy.\textsuperscript{21, 23} Though there was not a placebo group, the results obtained from the analysis of mix models suggest as well that the course of the illness was not modified by any of the treatment options tested.

CONCLUSION

HHHFNC was not superior to HSS in moderate bronchiolitis treatment with respect to severity scores, comfort or LOS. Neither it has reduced PICU admission rate respect to HSS but further studies with larger samples would be necessary to demonstrate this statement. Our study suggests that none of the therapies compared provide a real benefit to hospitalised infants less or equal to 6 months affected with moderate bronchiolitis.

Acknowledgements Elia Perez from Investigation Unit of the Hospital Universitario Fundación Alcorcon gracially provided assistance in the final statistical analysis. We thank all the nurses who assisted us with our work and, most of all, the families that participated in the study.

Contributors All authors contributed to the planning and writing of the manuscript. MBC performed the main part of statistical analysis and is the guarantor.

Funding All phases of this study were supported by a grant of the Department of Health, Social Policy and Equality of Spain, Grant EC11–437.

Competing interests None.

Ethics approval Ethics Committee of both participant hospitals.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

36 Al-Ansari K, Sakran M, Davidson BL, et al. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr 2010;157:630–4.